Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Zabini, Diana ^a   Nagaraj, Chandran ^a,c   Stacher, Elvira ^a   Lang, Irene M ^b   Nierlich, Patrick ^b   Klepetko, Walter ^b   Heinemann, Akos ^a   Olschewski, Horst ^a   Bálint, Zoltán ^a,c   Olschewski, Andrea ^a,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHEMOKINE RECEPTOR CXCR3; COLLAGEN TYPE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANGIOGENESIS; ARTERY ENDOTHELIUM; ARTICLE; BLOOD CLOT LYSIS; CALCIUM HOMEOSTASIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDARTERECTOMY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG EMBOLISM; MALE; PULMONARY ARTERY; PULMONARY ENDARTERECTOMY; PULMONARY HYPERTENSION; RECANALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CALCIUM; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL10; ENDARTERECTOMY; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; RECEPTORS, CXCR3;

EID: 84865192319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043793     Document Type: Article

References (61)

1. Humbert M, ((2010)) Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Pathophysiology. Eur Respir Rev 19(115): 59-63.
2. Lang I, ((2010)) Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. Br J Haematol 149(4): 478-483.
3. Sacks RS, Remillard CV, Agange N, Auger WR, Thistlethwaite PA, et al. ((2006)) Molecular biology of chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 18(3): 265-276.
4. Mayer E, Klepetko W, ((2006)) Techniques and outcomes of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3(7): 589-593.
5. Lang IM, Klepetko W, ((2009)) Update on chronic thromboembolic pulmonary hypertension, a frequently undiagnosed condition. Rev Esp Cardiol 62(2): 120-125.
6. Bonderman D, Jakowitsch J, Redwan B, Bergmeister H, Renner MK, et al. ((2008)) Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 28(4): 678-684.
7. Wynants M, Quarck R, Ronisz A, Alfaro-Moreno E, Van Raemdonck D, et al. (2012) Effects of c-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur Respir J doi:10.1183/09031936.00197511. In press.
8. Lang IM, Klepetko W, ((2008)) Chronic thromboembolic pulmonary hypertension: An updated review. Curr Opin Cardiol 23(6): 555-559.
9. Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, et al. ((2000)) Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15(2): 395-399.
10. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, et al. ((2004)) Chronic thromboembolic pulmonary hypertension. Eur Respir J 23(4): 637-648.
11. Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, et al. ((2006)) Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173(11): 1270-1275.
12. Suntharalingam J, Goldsmith K, van Marion V, Long L, Treacy CM, et al. ((2008)) Fibrinogen aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 31(4): 736-741.
13. Firth AL, Yao W, Ogawa A, Madani MM, Lin GY, et al. ((2010)) Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Cell Physiol 298(5): C1217-25.
14. Yi ES, Kim H, Ahn H, Strother J, Morris T, et al. ((2000)) Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162(4 Pt 1): 1577-1586.
15. Ellis CA, Malik AB, Gilchrist A, Hamm H, Sandoval R, et al. ((1999)) Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of gi-linked Ras/mitogen-activated protein kinase pathway. J Biol Chem 274(19): 13718-13727.
16. Garcia JG, Patterson C, Bahler C, Aschner J, Hart CM, et al. ((1993)) Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J Cell Physiol 156(3): 541-549.
17. Sakao S, Hao H, Tanabe N, Kasahara Y, Kurosu K, et al. ((2011)) Endothelial-like cells in chronic thromboembolic pulmonary hypertension: Crosstalk with myofibroblast-like cells. Respir Res 12: 109 doi:10.1186/1465-9921-12-109.
18. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, et al. ((2009)) Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 296(6): L870-8.
19. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, et al. ((1994)) Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 89(6): 2715-2721.
20. Ribatti D, ((2009)) Endogenous inhibitors of angiogenesis: A historical review. Leuk Res 33(5): 638-644.
21. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, et al. ((2003)) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47(3): 149-161.
22. Herve P, Fadel E, ((2006)) Systemic neovascularization of the lung after pulmonary artery occlusion: "decoding the da vinci code". J Appl Physiol 100(4): 1101-1102.
23. Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, et al. ((2001)) Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 164(2): 319-324.
24. Carmeliet P, ((2000)) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6(4): 389-395.
25. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, et al. ((1998)) Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 12(15): 1731-1738.
26. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, et al. ((1999)) Endostatin induces endothelial cell apoptosis. J Biol Chem 274(17): 11721-11726.
27. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, et al. ((2000)) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6(1): 41-48.
28. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, et al. ((2009)) Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114(19): 4272-4278.
29. McGuinness CL, Humphries J, Waltham M, Burnand KG, Collins M, et al. ((2001)) Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost 85(6): 1018-1024.
30. Singh I, Burnand KG, Collins M, Luttun A, Collen D, et al. ((2003)) Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: Rescue by normal bone marrow-derived cells. Circulation 107(6): 869-875.
31. Dible JH, ((1958)) Organisation and canalisation in arterial thrombosis. J Pathol Bacteriol 75(1): 1-7.
32. Wakefield TW, Linn MJ, Henke PK, Kadell AM, Wilke CA, et al. ((1999)) Neovascularization during venous thrombosis organization: A preliminary study. J Vasc Surg 30(5): 885-892.
33. Sevitt S (1970) Organic canalisation and vascularisation of deep vein thrombi studied with dyed-micropaque injected at necropsy. J Pathol 100(2): Pi.
34. Moser KM, Bloor CM, ((1993)) Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103(3): 685-692.
35. Hosokawa K, Ishibashi-Ueda H, Kishi T, Nakanishi N, Kyotani S, et al. ((2011)) Histopathological multiple recanalized lesion is critical element of outcome after pulmonary thromboendarterectomy. Int Heart J 52(6): 377-381.
36. Ogawa A, Firth AL, Yao W, Madani MM, Kerr KM, et al. ((2009)) Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 297(4): L666-76.
37. Tiruppathi C, Minshall RD, Paria BC, Vogel SM, Malik AB, ((2002)) Role of Ca2+ signaling in the regulation of endothelial permeability. Vascul Pharmacol 39(4-5): 173-185.
38. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, et al. ((2004)) Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A 101(38): 13861-13866.
39. Maruoka M, Sakao S, Kantake M, Tanabe N, Kasahara Y, et al. (2011) Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension. Int J Cardiol doi:10.1016/j.ijcard.2011.02.037. In press.
40. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA, ((1981)) Studies of human plate alpha-granule release in vivo. Blood 58(3): 607-618.
41. Fukami MH, Holmsen H, Kowalska MA, Niewiarowski S (2001) Platelet secretion. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors., editor. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins. 561-573.
42. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, et al. ((1993)) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177(6): 1809-1814.
43. Luster AD, Greenberg SM, Leder P, ((1995)) The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182(1): 219-231.
44. Firth AL, Yau J, White A, Chiles PG, Marsh JJ, et al. ((2009)) Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am J Physiol Lung Cell Mol Physiol 296(6): L979-86.
45. Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, et al. ((2011)) Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 117(2): 480-488.
46. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, et al. ((2001)) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107(1): 53-63.
47. Hou Y, Plett PA, Ingram DA, Rajashekhar G, Orschell CM, et al. ((2006)) Endothelial-monocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3. Exp Hematol 34(8): 1125-1132.
48. Colvin RA, Campanella GS, Sun J, Luster AD, ((2004)) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279(29): 30219-30227.
49. Mueller A, Meiser A, McDonagh EM, Fox JM, Petit SJ, et al. ((2008)) CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol 83(4): 875-882.
50. van Weering HR, de Jong AP, de Haas AH, Biber KP, Boddeke HW, ((2010)) CCL21-induced calcium transients and proliferation in primary mouse astrocytes: CXCR3-dependent and independent responses. Brain Behav Immun 24(5): 768-775.
51. De S, Razorenova O, McCabe NP, O'Toole T, Qin J, et al. ((2005)) VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A 102(21): 7589-7594.
52. Hofer E, Schweighofer B, ((2007)) Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 97(3): 355-363.
53. Davis GE, Senger DR, ((2005)) Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97(11): 1093-1107.
54. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A, ((1998)) Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 91(9): 3289-3299.
55. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, et al. ((1989)) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58(5): 933-943.
56. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, et al. ((1995)) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182(1): 155-162.
57. Yang L, Du J, Hou J, Jiang H, Zou J, ((2011)) Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer 11: 261 doi:10.1186/1471-2407-11-261.
58. Angiolillo AL, Sgadari C, Tosato G, ((1996)) A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 795: 158-167.
59. Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A, ((2009)) IP-10 induces dissociation of newly formed blood vessels. J Cell Sci 122(Pt 12): 2064-2077.
60. Auer-Grumbach M, Olschewski A, Papic L, Kremer H, McEntagart ME, et al. ((2010)) Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet 42(2): 160-164.
61. Grynkiewicz G, Poenie M, Tsien RY, ((1985)) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260(6): 3440-3450.